Trial Profile
Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Nov 2023 Planned End Date changed from 8 Oct 2023 to 31 Oct 2025.
- 01 Nov 2023 Planned primary completion date changed from 8 Oct 2023 to 31 Oct 2024.
- 13 Dec 2022 Primary endpoint has been met, (Overall response rate (ORR) defined as a partial response, very good partial response, complete response (CR) or stringent CR (sCR); as per Results presented at the 64th American Society of Hematology Annual Meeting and Exposition